68Ga-PSMA-617 PET/CT检出甲状腺癌来源的下腔静脉瘤栓
一例61岁女性放射性碘难治性分化型甲状腺癌患者,接受多靶点酪氨酸激酶抑制剂多纳非尼治疗12个月后出现耐药。因治疗选择有限,行68Ga-PSMA-617 PET/CT寻找潜在治疗靶点,显示下腔静脉内放射性摄取浓聚,随后确诊为瘤栓。
要点
- 放射性碘难治性分化型甲状腺癌TKI耐药后可考虑68Ga-PSMA-617 PET/CT评估靶点。
- 68Ga-PSMA-617 PET/CT下腔静脉浓聚提示甲状腺癌瘤栓可能。
- 甲状腺癌下腔静脉瘤栓为罕见表现,PET/CT有助发现。
核心结论
- 68Ga-PSMA-617 PET/CT可用于放射性碘难治性分化型甲状腺癌TKI耐药后评估潜在治疗靶点。
- 本例通过68Ga-PSMA-617 PET/CT发现下腔静脉内甲状腺癌来源瘤栓,属罕见病例。
研究设计与样本
- 个案报道:61岁女性放射性碘难治性分化型甲状腺癌患者,多纳非尼治疗12个月后耐药,行68Ga-PSMA-617 PET/CT。
主要发现
- 68Ga-PSMA-617 PET/CT显示下腔静脉内放射性示踪剂摄取浓聚,随后确诊为瘤栓。
临床怎么用
- 对放射性碘难治性分化型甲状腺癌TKI耐药、治疗选择有限者,可考虑68Ga-PSMA-617 PET/CT寻找潜在治疗靶点并评估瘤栓等特殊病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 61-year-old woman was diagnosed with progressive metastatic radioactive iodine refractory differentiated thyroid cancer and underwent multitargeted tyrosine kinase inhibitor (TKI) Donafenib therapy. After 12 months of therapy, she developed resistance to TKI. Considering the limited treatment options available, a 68Ga-prostate-specific membrane antigen (PSMA)-617 PET/CT was conducted for potential therapeutic target. 68Ga-PSMA-617 PET/CT showed an intense radiotracer uptake in inferior vena cava, which was subsequently confirmed as tumor thrombus. Thus, this patient is a rare case in which the tumor thrombus from thyroid cancer was discovered in inferior vena cava via 68Ga-PSMA-617 PET/CT.
引用
- Li H, Liu Y, Zang J, et al. Inferior Vena Cava Tumor Thrombus From Thyroid Cancer Detected by 68Ga-PSMA-617 PET/CT. Clin Nucl Med. 2021. PMID: 33351509. doi:10.1097/RLU.0000000000003497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。